Abstract
Introduction
Dendritic cells (DCs) are specialized antigen-presenting cells and play an important role in immune responses [1] . These cells provide a link between the innate and adaptive immune system. The precursors originating from the bone marrow and the thymus can differentiate into DCs. DCs enter the circulation and reside to the peripheral tissue. After being connected with immune stimulants, DCs take up and process antigens in peripheral tissues and then migrate to secondary lymphoid organs, where they activate naive T cells. The maturation
MTT assay
To determine the metabolic activity of cells, MTT assays were performed. Cells were seeded in 96-well plates at a density of 1 × 10³ cells per well. Wells containing culture medium only served as blank controls for non-specific dye reduction. For the measurement MTT solution was added to each well to a final concentration of 0.5 mg/ml. After 4 h of incubation at 37°C, the medium was removed and the formazan crystals were dissolved in DMSO. Absorbance was measured at 490 nm using a microplate reader.
Flow cytometry
The surface expression of antigen markers was performed by flow cytometry. DCs were collected and resuspended in PBS at a concentration of 2×10 
Cell migration assay
Cell migration was determined in Boyden chambers as described. Briefly, cells were serum-starved for 8 h and then exposed to LPS, Ang II and negative control for 12 h. Then 4×10 4 cells were seeded to the upper chamber. Cell migration was allowed to proceed for 16 h at 37℃ in 5% CO 2 . Cells migrated to the lower surface of the filter were stained 1% crystal violet in 2% ethanol for 20 min, and quantified by cell counting under high magnification. 
Co-culture of lymphocytes and DCs
Single-cell suspensions from spleen of BALB/c mice were obtained by grinding and filtration through nylon mesh. The lymphocytes were enriched with Ficoll (TBDscience). Lymphocytes (1×10 6 /mL) were stained with CFSE and then co-cultured with C57BL/6 bone marrow-derived DCs (1×10 5 /mL) after Mitomycin C treatment (Roche). Five days later, harvested cells were stained with PE-conjugated anti-CD3 (eBioscience) and T cells proliferation was evaluated by flow cytometry.
Western blot analysis
Total protein was isolated from different treated DCs. Cells were collected, repeatedly frozen and thawed in NP-40 lysis buffer with 1% PMSF. The lysate was centrifuged at 12,000×g for 10 min at 4℃, and the supernatant was collected. Thirty μg protein per sample was loaded on a 10% SDS-PAGE gel and transferred onto nitrocellulose membranes. After being blocked with 5% nonfat milk for 30 min, the membranes were incubated with primary antibodies as indicated overnight and then incubated with horseradish peroxidaseconjugated secondary antibody for 1 h. The blots were developed with an enhanced chemiluminescence detection system (Beijing Sage creation) and the bands were scanned, and densitometry analysis was performed with the software Image J 2x.
Statistical analysis
Students paired t-test was used to determine the significance of differences between means, and P< 0.05 was taken as indicating statistical significance.
Results

Ang II inhibits the proliferation of DCs
To evaluate the proliferation of DCs in response to Ang II and LPS stimulation, we treated DCs with Ang II (100 ng/ml) or LPS (200 ng/ml) after overnight starvation. MTT analysis revealed that LPS significantly inhibited the proliferation of DCs during 12-24 h, whereas Ang II only markedly inhibited this effect after 24 h. Notably, the proliferation of DCs was significantly higher in Ang II treatment than in LPS treatment at 24 h. These results indicate that Ang II has a lower inhibitory ability on DC proliferation than LPS (Fig. 1) .
Ang II stimulates the phenotypic maturation of DCs
To investigate the effect of LPS and Ang II on DCs maturation, DCs were treated with Ang II (100 ng/ml) or LPS (200 ng/ml) for 12-48 h. The maturation surface molecules of DCs, including MHCII, CD40 and CD80, were detected by flow cytometry. As shown in Fig. 2 , both Ang II and LPS significantly increased the phenotypic maturation of DCs at different time points. After Ang II stimulation, the levels of MHCII and CD40 were peaked at 12 h, whereas CD80 was peaked at 24 h. While LPS treatment led to a marked increase in the levels of MHCII, CD40 and CD80 at 12 h compared to 0 h, peaked at 24 h, and then decreased almost to the baseline at 48 h. Interestingly, the levels of MHCII and CD40 were significantly lower in Ang II treatment than that in LPS treatment at 12 and 24 h.
Ang II promotes the migration of DCs
To determine the effect of Ang II and LPS on the migration of DCs, We treated DCs with Ang II (100 ng/ml) or LPS (200 ng/ml) for 48 h, and transwell assay was performed. Both Ang II and LPS significantly promoted the migration of DCs (about 1.7-fold and 2.0-fold, respectively) as compared with control, and there was no marked difference between Ang II and LPS treatment (Fig. 3) .These results suggest Ang II displays a similar effect with LPS on migratory activity.
Ang II inhibits the phagocytosis of DCs
Maturation of DCs is associated with decreased endocytic ability. To further examine the Ang II and LPS on the phagocytosis of DCs, we treated DCs with Ang II (100 ng/ml) or LPS (200 ng/ml) for 48 h. The phagocytosis was measured by flow cytometry. As shown in Fig. 4 , Ang II and LPS significantly decreased the endocytic ability of DCs by 50% and Fig. 1 . Ang II inhibits the proliferation of DCs. DCs were treated with Ang II (100 ng/ml) or LPS (200 ng/ml) after overnight starvation. MTT analysis of cell proliferation was performed. Data were expressed as mean ± SEM from three independent experiments. *P< 0.05 versus control.
# P< 0.05 versus LPS. 65%, respectively, and there was no marked difference between Ang II and LPS treatment, indicating that Ang II and LPS have a similar inhibitory effect on phagocytosis of DCs.
Ang II induces the cytokine secretion of DCs
To test the effect of Ang II and LPS on the production of proinflammatory cytokines including IL-6 and IFN-γ, DCs were treated with Ang II (100 ng/ml) or LPS (200 ng/ml) for 48 h, and protein concentration was determined by ELISA. As shown in Fig. 5 , both Ang II and LPS stimulation resulted in a significant increase of both IL-6 and IFN-γ compared with control in DCs. The level of IFN-γ was significantly higher in Ang II stimulation than that in LPS.
Ang II promotes DC-mediated T cell proliferation
To assess the effect of Ang II and LPS on DC-mediated T cell proliferation, we cocultured DCs and T lymphocyte and then treated with Ang II and LPS. Flow cytometry was performed with PE-conjugated anti-CD3. As shown in Fig. 6 , both LPS-and Ang II-treated DCs significantly increased the proliferation of T cells by about 7-and 4-fold, respectively. The DC-mediated proliferation of T cells was also markedly lower in Ang II treatment and that in LPS stimulation. The effect of Ang II on activation of NF-κB, MAPKs and STAT1 in DCs. DCs were treated with Ang II (100 ng/ml) or LPS (200 ng/ml) for different time-points. Representative Western blots showed expression levels of total and phospho-p65/NF-kB, total and phospho-ERK1/2, and total and phospho-STAT3 (a), and total and phospho-JNK1/2, total and phospho-p38 MAPK (b). The intensity of protein bands was quantified and shown as the ratio of phosphorylated protein/total protein to control (0 min) after normalization by β-actin (right). Data were expressed as mean±SEM for three independent experiments. *P < 0.05, # P < 0.05 versus LPS.
Ang II activated DCs through multiple signaling pathways
To elucidate the molecular mechanism for Ang II and LPS to regulate DCs, we examined activation of NF-κB, mitogen-activated protein kinase (MAPK) and signal transducers and activators of transcription (STAT1) signaling, which are known to play a critical role in DC antigen presentation and T-cell-dependent immune responses. As shown in Fig.  7 , Ang II treatment significantly increased the levels of p65/NF-kB, ERK1/2 and STAT1 phosphorylation, but had no effect on the phosphorylation of JNK1/2 and p38 MAPK compared with control. LPS treatment markedly increased the levels of phosphorylated p65/ NF-kB, ERK1/2, STAT1, JNK1/2 and p38 MAPK (Fig. 7) . These results suggested that Ang II and LPS induce the activation of DCs via different signal pathways with some overlapping.
Discussion
In the present study, we investigated the potential role of Ang II in promoting DC activation. We found that Ang II has similar impact to LPS in the regulation of DCs. Ang II treatment significantly suppressed the proliferation and phagocytic activity of DCs, but promoted the DC maturation, migration and the expression of pro-inflammatory cytokines by DCs. Ang II also promoted DC-mediated T cell proliferation. These effects were associated with activation of p65/NF-κB, ERK1/2 and STAT1 signaling pathways in DCs.
The roles of renin-angiotensin-aldosterone system (RASS) in blood pressure regulation have been well documented. The current rationale for routine use of angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitors (ACEI) is to lower the blood pressure in hypertensive patients. The pro-inflammatory actions of Ang II have received increasing attention. Elevated plasma level of Ang II has been documented in patients with hypertension, myocardial infarction and heart failure [10] [11] [12] . Ang II is able to induce the generation of reactive oxygen species and the activation MAPKs and NF-κB pathways in the heart, consequently resulting in cardiac hypertrophy, fibrosis and dysfunction [13] .
DCs are key modulators of immunity, pivotal in directing innate and adaptive immune responses, and play a regulatory role for DCs in cardiovascular diseases (CVD)-associated immune responses. In general, most patient studies show decreased blood DC numbers in CAD patients. One possibility for the decrease in circulating DCs might be their enhanced recruitment to the disease sites, such as plaque or the ischemic heart [14] . However, high levels of DCs were found in patients with hypertension [15] . T cells have been described to contribute to hypertension, a process that likely involves the priming by DCs [16] . Vinh et al. reported that the number of activated DCs was increased in spleen and lymph nodes of hypertensive mice. Abatacept (CD28 blocker) administration significantly prevents Ang IIinduced hypertension in mice, supporting contribution of DCs to Ang II-induced hypertension [17] . Moreover, in human atherosclerotic plaques, mature DCs accumulate within the plaque shoulder where they produce T-cell chemotactic (CCL19 and CCL21) and proinflammatory cytokines (IL-12, IL-23, TNF-α) [18] [19] [20] . Importantly, DCs have the unique ability to induce T-cell responses by presenting antigens to naive T cells. For example, DCs, isolated from the aorta and the valves of wild-type mice, have the capacity to present antigens to CD8 + T cells, indicating that these cells are able to elicite a T-cell response [21] . Notably, DCs express Ang II receptors. Ang II treatment can induce human and murine DC maturation and activation in vivo and in vitro [22] . Consistent with these findings, our results demonstrated that Ang II has important functions in the regulation of the proliferation, maturation, migration, phagocytosis, and communication with T cells of DCs, and these effects were, at least in part, due to the activation of NF-κB, ERK1/2 and STAT1 signalling pathways.
In conclusion, here we aimed to investigate the effect of Ang II on the regulation of DCs and the underlying mechanisms. We found that both Ang II and LPS are important regulators of DCs during the inflammatory responses. These findings may give a comprehensive insight the role of DCs in Ang II-induced cardiovascular disease and a potential therapeutic strategy for the suppression of immune diseases.
